Axsome医疗 AXSM 深 沪
已收盘 09-18 16:00:00 美东时间
91.54
+0.600
+0.66%
华盛通- 最 高92.50
- 今 开90.98
- 成交量 34.29万股
- 最 低 89.24
- 昨 收 90.94
- 总市值 43.37亿
- 52周最高 98.40
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 55.02
- 委 比 60.00%
- 总股本 4737.44万
- 历史最高 109.94
- 量 比 0.94
- 振 幅 3.58%
- 历史最低 1.94
- 每 手 1
- 风险率 9.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Axsome Therapeutics (AXSM) Gets a Buy from Cantor Fitzgerald
In a report released on September 4, Charles Duncan from Cantor Fitzgerald main...
09-06 19:27
Axsome migraine therapy undergoes FDA review again
Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday that the U.S. Food and Drug Administration (FDA) accepted its resubmitted marketing application for its experimental migraine therapy AXS-07. The ...
09-04 19:26
Unveiling 14 Analyst Insights On Axsome Therapeutics
Across the recent three months, 14 analysts have shared their insights on Axsom...
08-22 22:00
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Axsome Therapeutics (NASDAQ:AXSM) has reached an agreement with Sandoz (OTCQX:SDZNY) to dismiss the patent litigation related to Axsome’s product Sunosi (solriamfetol), it said on Wednesday. The litig...
08-21 19:51
Investors Interested In Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Revenues
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) price-to-sales (or "P/S") ratio of 14...
08-07 20:02
快讯 | Axsome Therapeutics公司: RBC将目标价从131美元下调至130美元。
Axsome Therapeutics Inc : RBC Cuts Target Price to $130 From $131
08-06 14:43
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.
08-06 00:57
Axsome Therapeutics Q2 2024 Adj. EPS $(1.12) Beats $(1.34) Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.34) by 16.42 percent.
08-05 19:12
快讯 | Axsome Therapeutics公司预计在2024年第三季度提交Axs-14用于纤维肌痛的新药申请。
Axsome Therapeutics Inc: Nda Submission for Axs-14 in Fibromyalgia Expected 3Q ...
08-05 19:03
Axsome Therapeutics Q2 Sales $87.166M Beat $86.659M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly sales of $87.166 million which beat the analyst consensus estimate of $86.659 million by 0.58 percent. This is a 86.65 percent increase over sales of $46.700 million
08-05 19:01
